Amgen: Low LDL Levels With Repatha Did Not Affect Cognitive Function In Study – Nasdaq


NPR

Amgen: Low LDL Levels With Repatha Did Not Affect Cognitive Function In Study
Nasdaq
(RTTNews.com) – Amgen Inc. ( AMGN ) announced results from the Repatha or evolocumab cognitive function trial (EBBINGHAUS) evaluating the impact on cognitive function in 1,974 patients enrolled in the Repatha cardiovascular outcomes study, …
Cholesterol drug cuts heart risks, spurs new debate on cost10News
Cholesterol-Slashing Drug Can Protect High-Risk Heart Patients, Study FindsNew York Times
A pricey drug cuts cardiovascular risks in clinical trial — but will insurers cover it?PBS NewsHour
Sarasota Herald-Tribune –NPR –FiercePharma –MedPage Today
all 121 news articles »

View original article
Author:

Powered by WPeMatico